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Aim: To identify a potential efficacy–effectiveness gap and possible explanations (drivers 
of effectiveness) for differences between results of randomized controlled trials (RCTs) and 
observational studies investigating glucose-lowering drugs.
Methods: A systematic literature review was conducted in English language articles published 
between 1 January, 2000 and 31 January, 2015 describing either RCTs or observational studies 
comparing glucagon-like peptide-1 analogs (GLP-1) with insulin or comparing dipeptidyl pep-
tidase-4 inhibitors (DPP-4i) with sulfonylurea, all with change in glycated hemoglobin (HbA1c) 
as outcome. Medline, Embase, Current Content, and Biosis were searched. Information on effect 
estimates, baseline characteristics of the study population, publication year, study duration, and 
number of patients, and for observational studies, characteristics related to confounding adjust-
ment and selection- and information bias were extracted.
Results: From 312 hits, 11 RCTs and 7 observational studies comparing GLP-1 with insulin, 
and from 474 hits, 16 RCTs and 4 observational studies comparing DPP-4i with sulfonylurea 
were finally included. No differences were observed in baseline characteristics of the study 
populations (age, sex, body mass index, time since diagnosis of type 2 diabetes mellitus, and 
HbA1c) or effect sizes across study designs. Mean effect sizes ranged from −0.43 to 0.91 and 
from −0.80 to 1.13 in RCTs and observational studies, respectively, comparing GLP-1 with 
insulin, and from −0.13 to 2.70 and −0.20 to 0.30 in RCTs and observational studies, respec-
tively, comparing DPP-4i and sulfonylurea. Generally, the identified observational studies held 
potential flaws with regard to confounding adjustment and selection- and information bias.
Conclusions: Neither potential drivers of effectiveness nor an efficacy–effectiveness gap were 
identified. However, the limited number of studies and potential problems with confounding 
adjustment, selection- and information bias in the observational studies, may have hidden a 
true efficacy-effectiveness gap.
Keywords: efficacy–effectiveness gap, diabetes mellitus, type 2, glucose-lowering drugs, 
hemoglobin A1c, literature review
Introduction
The beneficial effects of drugs can be divided into efficacy and effectiveness. The 
efficacy of a drug describes the biological effect and can be seen as the effect evaluated 
under optimal conditions in randomized controlled trials (RCTs). The effectiveness of 
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a drug describes the effect under circumstances of routine 
clinical practice. The efficacy–effectiveness gap refers to 
the difference between the (in theory) largest possible effect 
of a drug and its effect in clinical practice.1–4 A comparison 
of RCTs and observational studies can be used as a model 
to investigate and better understand the efficacy–effective-
ness gap.
The population in routine clinical practice may differ 
from the often highly selected study population included 
in RCTs,5–10 which could be one possible reason for an 
efficacy–effectiveness gap. Observational studies usually 
reflect the population seen in clinical practice, and also other 
factors such as the delivery of care, adherence to treatment, 
and time between treatment and assessment of the outcome 
are often more similar to ordinary clinical practice than that 
which is seen in RCTs because observational studies are often 
based on real-world data.11 Discrepancies in the results from 
RCTs and observational studies may be due to biases in the 
observational study design,12–15 but may also be explained 
by an efficacy–effectiveness gap. An understanding of the 
efficacy–effectiveness gap is important for patients, health 
care professionals, payers, regulators, and the pharmaceutical 
industry to provide effective treatments.3,16
The aim of this literature review is to identify a potential 
efficacy–effectiveness gap, by comparing RCTs and obser-
vational studies investigating glucose-lowering drugs in 
relation to change in glycated hemoglobin (HbA1c), and if 
such a gap exists, to investigate whether it can be explained 
by differences in the baseline characteristics of the study 
populations or other features that characterize the RCTs and 
observational studies.
Methods
A systematic literature search was performed to identify 
RCTs and observational studies fulfilling the following 
inclusion criteria: published between 1 January, 2000 and 
31 January, 2015 in English language and compared either 
glucagon-like peptide-1 analogs (GLP-1) with insulin or 
dipeptidyl peptidase-4 inhibitors (DPP-4i) with sulfonyl-
urea, all with change in HbA1c as an outcome. The chosen 
comparator groups were to compare second-line (DPP-4i 
and sulfonylurea) and third-line (GLP-1 and insulin) treat-
ments, respectively.17 Especially, observational studies are 
difficult to identify, and therefore, more search terms were 
used to identify such studies, and covered both prospective 
and retrospective studies, as well as cohort and case–control 
studies. The key terms and the combination of these can be 
found in the supplementary material. The following databases 
were used: Medline, Embase, Current Content, and Biosis. 
The search strategy was developed by one of the reviewers 
(MZA) and a librarian. References of the identified studies 
were searched to identify additional relevant studies.
The studies identified through the literature search were 
screened on title and abstract by two reviewers independently. 
Disagreements were settled through discussions and consen-
sus. Full text was read by a single reviewer, who extracted 
information on the baseline characteristics of the study 
population, other features that described the included stud-
ies, and effect estimate from text and tables in the included 
studies. Some of the hits from the search were abstracts 
published in relation to scientific conferences. Information 
from conference abstracts was not included in this review. If 
a conference abstract seemed relevant, an attempt was made 
to identify the published studies related to the conference 
abstract by web search and by contacting the authors of the 
conference abstract.
Post hoc, it was decided to exclude studies comparing 
DPP-4i with sulfonylurea during Ramadan in Muslim popu-
lations (three RCTs and six observational studies) because 
we did not want to compare across fasting and nonfasting 
studies and to exclude studies with fast-acting insulin (five 
RCTs) because we did not want to compare across fast-
acting and basal insulins. Studies investigating mixed insulin 
(combination of fast-acting and intermediate/long-acting) 
were included.
Post hoc exclusion criteria were applied as we gained 
knowledge when working on the review. Importantly, none 
of the post hoc exclusion criteria are in conflict with the 
initial inclusion criteria and they only narrow the inclusion 
criteria further.
If the identified RCTs and the observational studies 
included treatment arms of other drugs or placebo, only 
information about the relevant treatment arms was extracted. 
If several publications were based on the same study popula-
tion, but with different follow-up time, the information on 
patient characteristics was extracted once, while each effect 
size at different time points was extracted. If studies included 
several analyses, for example, intention-to-treat and per pro-
tocol, the analysis that was reported as the primary analysis 
was extracted. Two RCTs18,19 included a once-daily and a 
twice-daily insulin group; GLP-1 vs. twice-daily insulin is 
reported later. Two RCTs20,21 included a high and a low dose 
of GLP-1 and DPP-4i, respectively; high dose vs. comparator 
is reported later. Generally, the data extraction protocol was 
based on the Cochrane Handbook:22 Baseline characteris-
tics were extracted as mean and standard deviation (SD) or 
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 proportion. A few studies reported median and interquartile 
range, and in those cases, SD was derived by dividing inter-
quartile range by 1.35.22 The reported outcome is the differ-
ence in change in HbA1c between treatment groups. When 
extracting effect estimates, the following prioritization was 
used: 1) effect estimate and 95% confidence interval (CI) as 
written in text; 2) effect estimate and 95% CI as written in a 
table; 3) if, for example, one-sided interval was given, then 
the two-sided 95% CI was calculated; 4) if no effect size with 
CI was given, these were calculated from the effect estimate 
and SD or standard error of the mean (SEM) in each treat-
ment group; 5) if no SD or SEM, but a p value was given, 
then z values were calculated, and from this SEM and 95% 
CI; and 6) if only an effect estimate was reported and no CI 
or a p value, only the point estimate was used.
For the observational studies, additional information was 
extracted: confounding adjustment, analysis of initiator by 
having a “wash-out” period, selection bias related to clear 
and reasonable inclusion criteria or handling of missing data, 
and information bias related to the assessment of exposure 
and outcome. Comprehensive methods to assess quality of 
observational studies, such as, for example, ACROBATE-
NRSI,23 were not deemed necessary because the aim was 
not to have an estimate of the overall treatment effect across 
studies, but rather to look at signals of an efficacy–effective-
ness gap and potential drivers of such a gap. In relation to 
this, pooled estimates of the study characteristics and the 
effect estimates were not performed. The literature search 
and inclusion of studies did not strive to get homogeneous 
studies suitable for pooled estimates. Instead, baseline char-
acteristics and effect estimates were handled descriptively. 
The overlap of patient characteristics and effect estimate 
was used to assess if difference was present across studies. 
A difference >0.4% units is acknowledged as a clinically 
meaningful difference in HbA1c24 and was used to evaluate 
an efficacy–effectiveness gap.
Results
The search for studies comparing GLP-1 with insulin showed 
312 hits, of which 19 publications were included. However, 
the three publications by Diamant et al25–27 were based on 
the same RCT, but with different follow-up time, and the 
study by Thayer et al28 included two cohorts, which were 
reported separately later. Hence, 13 publications described 
11 individual RCTs18–20,25–27,29–35 and 6 publications described 
7 individual observational studies28,36–40 (Figure 1). The study 
duration ranged from 16 to 156 weeks and from 26 to 102 
weeks in RCTs and observational studies, respectively, and 
the number of participants ranged from 69 to 1028 and from 
47 to 51,977, respectively. Among the 312 hits, 9 were confer-
ence abstracts of observational studies, of which 1 was among 
the included observational studies as a research article. The 
authors of the other conference abstracts were contacted; one 
author replied, and no additional full-text study was identified.
The search for studies comparing DPP-4i with sulfo-
nylurea showed 474 hits, of which 23 publications were 
included. However, the publications by Nauck et al,41 Seck 
et al,42 Ferrannini et al,43 and Matthews et al,44 and the two 
publications by Göke et al,45,46 respectively, were based on the 
same RCTs with different follow-up time. Hence, 19 publica-
tions described 16 individual RCTs21,41–58 and 4 publications 
described 4 individual observational studies59–62 (Figure 1). 
Figure 1 Flow chart.
Notes: (A) Studies comparing glucagon-like peptide-1 with insulin. (B) Studies comparing dipeptidyl peptidase-4 inhibitors with sulfonylurea.
Abbreviation: RCTs, randomized controlled trials.
Hits from literature search: 312
A B
Removed duplicates: 134
Removed after reading titles: 71
Removed after reading abstracts: 71
Removed after reading full text: 11
Found in references: 2
Suggested by reviewer: 1
Conference abstracts only: 9
Titles read: 178
Abstract read: 107
Full text read: 27
Finally included: 13 papers describing 11 RCTs
6 papers describing 7 observational studies
Included papers: 16
Hits from literature search: 474
Titles read: 254
Abstract read: 124
Full text read: 23
Finally included: 19 papers describing 16 RCTs
Included papers: 16
Removed duplicates: 220
Removed after reading titles: 130
Removed after reading abstracts: 80
Removed after reading full text: 7
Found in references: 7
Conference abstracts only: 21
4 papers describing 4 observational studies
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The study duration ranged from 4 to 104 weeks and from 
24 to 52 weeks in RCTs and observational studies, respec-
tively, and the number of participants ranged from 33 to 3118 
and from 69 to 16,832, respectively. Among the 474 hits, 4 
and 17 were conference abstracts of RCTs and observational 
studies, respectively, of which 2 were among the included 
RCTs as research articles. The authors of the other confer-
ence abstracts were contacted; none of them replied, and no 
additional full-text study was identified.
More detailed information on the included studies is 
found in Tables S1–S4.
Table 1 holds information on study population char-
acteristics of the 17 individual studies (10 RCTs and 
7 observational studies) and the effect estimates from the 
18 publications comparing GLP-1 with insulin. Table 2 
holds information on study population characteristics of the 
20 individual studies (16 RCTs and 4 observational studies) 
and the effect estimates of the 23 publications comparing 
DPP-4i with sulfonylurea.
Characteristics of observational studies
Of the 11 individual observational studies,28,36–40,59–62 4 were 
prospective39,60–62 and 7 were based on registries.28,36–38,40,59 
Information of exposure in the prospective studies was 
based on doctor’s records of prescription, whereas exposure 
in registry studies was based on databases with informa-
tion on prescription36–38,40,59 or claims.28 The outcome in all 
studies was based on the clinical measure of HbA1c. The 
inclusion criteria in the studies were primarily based on 
previous medication, but also age and comorbidity were 
used in most studies. The observational studies analyzed 
patients who initiated either GLP-1 or insulin, or DPP-4i or 
sulfonylurea, respectively. Five of the observational studies 
excluded patients if information was missing,28,36–38 while 
the other six studies did not mention how missing data were 
handled.39,40,59–62 Five of the observational studies used mul-
tivariable regression38–40,60 or propensity score matching37 to 
adjust for potential confounding, although Karagianni et al39 
only included body mass index (BMI) and age in the model. 
Unadjusted effect estimates were reported in the remaining 
six observational studies.28,36,59,61,62 Generally, the design of 
the included observational studies was deemed suboptimal 
regarding confounding adjustment and the potential for 
selection- and information bias. However, two observational 
studies – one study37 comparing GLP-1 with insulin and 
another study60 comparing DPP-4i and sulfonylurea – were 
Table 1 Characteristics of RCTs and observational studies comparing glucagon-like peptide-1 with insulin
Authors Duration, 
weeks
N Age, 
years
Men, 
%
Body mass 
index,  
kg/m2
Time since 
diagnosis 
of type 2 
diabetes 
mellitus, 
years
Baseline 
HbA1c, 
%
Mean effect 
(95% confidence 
interval)a
Randomized 
controlled 
trials
Barnett et al30 16 138 54.9 (9.1) 47.1 31.1 (4.7) 7.4 (5.9) 9.0 (1.1)
−0.01 (−0.17, 0.15)
Bergenstal et al18 24 248 53.0 (10.3) 48.0 33.9 (7.3) 9.3 (5.8) 10.3 (1.7) 0.91 (0.59, 1.23)
Nauck et al20 24 667 57.5 (9.0) 51.7 32.5 (5.3) 9.5 (6.0) 8.4 (0.9)
−0.14 (−0.28, −0.01)
Davies et al32 26 234 56.5 (9.1) 68.4 34.1 (5.3) 8.7 (4.5) 8.6 (0.7) 0.01 (−0.24, 0.26)
Davies et al19 26 216 58.5 (10.0) 66.4 33.7 (4.7) 7.5 (5.5) 8.4 (0.9)
−0.42 (−0.63, −0.21)
Diamant et al27 26 456 58.0 (9.5) 53.5 32.3 (5.1) 7.9 (5.0) 8.3 (1.1)
−0.16 (−0.29, −0.03)
Heine et al29 26 535 58.9 (9.1) 55.8 31.4 (4.5) 9.6 (5.9) 8.3 (1.0) 0.02 (−0.12, 0.16)
Inagaki et al33 26 427 56.8 (10.8) 67.9 26.2 (3.9) 9.0 (6.0) 8.5 (0.8)
−0.43 (−0.59, −0.26)
Russell-Jones et al35 26 466 57.6 (10.0) 58.5 30.4 (5.3) 9.5 (6.1) 8.3 (0.9)
−0.24 (−0.08, −0.39)
Bunck et al31 52 69 58.4 (8.0) 65.2 30.5 (3.8) 4.9 (4.2) 7.5 (0.6)
−0.10 (−0.54, 0.34)
Weissman et al34 52 725 55.5 (9.5) 56.1 33.1 (5.5) 8.8 (6.3) 8.1 (0.9) 0.11 (−0.04, 0.27)
Diamant et al26 84 456 58.0 (9.5) 53.5 32.3 (5.1) 7.9 (5.0) 8.3 (1.1)
−0.18 (−0.33, −0.02)
Diamant et al25 156 456 58.0 (9.5) 53.5 32.3 (5.1) 7.9 (5.0) 8.3 (1.1)
−0.20 (−0.39, −0.02)
Observational 
studies
Karagianni et al39 26 47 62.0 (8.6) 34.0 34.4 (5.6) 11.9 (7.1) 8.4 (1.6)
−0.80 (−1.84, 0.24)
Horton et al36 36 38,678 60.4 (13.3) 46.9 34.4 (9.1) – 8.6 (2.2) 0.50 (0.46, 0.54)
Thayer et al28,b 36 861 53.0 (8.9) 55.7 – – 9.0 (6.1) 0.53 (–)
Thayer et al28,b 52 1709 55.8 (11.0) 54.7 – – 8.7 (1.7) 1.13 (–)
Pawaskar et al37 52 5366 58.0 (–) 46.3 36.7 – 8.1 (–)
−0.20 (–)
Hall et al38 52 2965 60.7 (11.4) 61.9 33.7 (6.5) 8.8 (5.7) 9.6 (3.8) 0.13 (−0.11, 0.38)
Bounthavong et al40 102 51,977 64.2 (10.4) 96.8 33.0 (6.7) – 8.8 (2.0)
−0.32 (−0.47, −0.18)
Notes: Data shown as mean (standard deviation) unless specified otherwise. Diamant et al25–27 are based on the same RCTs, but with different follow-ups. aThe difference in 
change in HbA1c between treatment groups. bTwo cohort studies described in the same publication. – indicates data not reported.
Abbreviations: HbA1c, glycated hemoglobin; RCTs, randomized controlled trials.
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explicit about the conducted analysis, including confounding 
adjustment, and gave information about possible selection 
bias and information bias. Neither the effect estimate nor 
the patient characteristics of these studies37,60 were different 
from the other observational studies comparing GLP-1 with 
insulin or comparing DPP-4i and sulfonylurea, respectively.
Characteristics of the study populations 
across study designs
The study populations did not differ across RCTs and obser-
vational studies with regard to age, sex ratio, BMI, time since 
diagnosis of type 2 diabetes mellitus, and baseline HbA1c nei-
ther in the studies that compared GLP-1 with insulin nor in the 
studies that compared DPP-4i with sulfonylureas. Generally, 
this goes for both means and SDs. One exception is HbA1c 
among studies of GLP-1 and insulin, where the HbA1c dis-
tribution in the observational studies was more heterogeneous 
than in the RCTs. Also, a few outliers should be mentioned. 
Among studies comparing GLP-1 with insulin, the observa-
tional study by Bounthavong et al40 included almost only men 
and BMI was low in the RCT by Inagaki et al33 (explained 
by a Japanese population). The range of the distribution of 
HbA1c is generally wider in the observational studies than 
in the RCTs. This indicates that the study population is more 
heterogeneous with regard to HbA1c in the observational 
studies. However, the mean of HbA1c is of similar magnitude 
across study designs. An outlier among the studies compar-
ing DPP-4i with sulfonylurea is the RCT by Shimoda et al,58 
which included a higher proportion of women compared to 
the other studies. Unfortunately, information on time since 
diagnosis of type 2 diabetes mellitus was only available in two 
of the observational studies comparing GLP-1 with insulin.
Effect estimates across study designs
Effect estimates did not differ across RCTs and observational 
studies, both for studies comparing GLP-1 with insulin 
(Figure 2) and studies comparing DPP-4i with sulfonylurea 
(Figure 3). Among studies comparing GLP-1 with insulin, 
a few studies18,28,36 reported findings outside the 95% CI of 
the other studies; in the observational study by Horton et al36 
and the two cohorts in the observational study by Thayer 
et al,28 no adjustment for confounding was done. This could 
Table 2 Characteristics of RCTs and observational studies comparing dipeptidyl peptidase-4 inhibitors with sulfonylurea
Authors Duration, 
weeks
N Age,  
years
Men, 
%
Body mass 
index,  
kg/m2
Time since 
diagnosis 
of type 2 
diabetes 
mellitus, 
years
Baseline 
HbA1c,  
%
Mean effect 
(95% confidence 
interval)a
Randomized 
controlled  
trials
Kim et al55 4 33 57.8 (6.7) 58.6 25.5 (2.8) 5.3 (4.7) 7.2 (0.5) 0.00 (–)
Shimoda et al58 12 50 63.1 (12.4) 31.0 25.1 (3.9) – 7.4 (0.6) 2.70 (−0.10, 5.50)
Srivastava et al50 18 50 – – 25.9 (3.3) – 8.3 (0.5) 0.54 (0.02, 1.06)
Derosa et al57 26 167 58.1 (9.4) 49.1 27.8 (1.5) 6.7 (4.1) 7.8 (0.8) 0.00 (–)
Jeon and Oh49 32 101 54.5 (10.7) 64.7 22.9 (6.0) 5.9 (1.7) 8.1 (1.0) 0.06 (−0.42, 0.54)
Derosa et al53 52 453 – 49.6 27.3 (2.1) 5.0 (2.0) 8.3 (1.2) 0.20 (−1.73, 2.13)
Rosenstock et al54 52 441 70.0 (4.3) 44.9 29.8 (4.5) 6.1 (6.3) 7.5 (0.7)
−0.05 (−0.23, 0.13)
Nauck et al41 52 1172 56.7 (9.6) 59.2 31.3 (5.1) 6.4 (5.8) 7.7 (0.9) 0.00 (–)
Göke et al45 52 858 57.6 (10.3) 51.8 31.4 (5.9) 5.5 (4.6) 7.7 (0.9) 0.06 (−0.05, 0.16)
Ferrannini et al43 52 3118 57.5 (9.13) 53.5 31.8 (5.3) 5.7 (5.1) 7.3 (0.7) 0.09 (0.03, 0.15)
Filozof and Gautier48 52 1007 59.5 (10.0) 52.0 31.0 (5.0) 6.6 (5.2) 8.5 (1.0) 0.04 (−0.11, 0.20)
Arjona et al52 54 426 64.5 (9.9) 57.0 26.8 (4.8) 10.4 (7.7) 7.8 (0.7)
−0.11 (−0.29, 0.06)
Arjona et al51 54 129 59.5 (9.5) 59.7 26.8 (5.0) 17.5 (8.9) 7.9 (0.7) 0.15 (−0.18, 0.49)
Ahrén et al56 104 609 54.4 (9.9) 48.8 32.5 (5.5) 5.9 (4.8) 8.1 (0.8) 0.08 (–)
Del Prato et al21 104 1759 55.5 (9.7) 50.8 31.2 (5.3) 5.5 (4.8) 7.6 (0.6)
−0.13 (−0.24, −0.02)
Foley and Sreenan47 104 1092 54.8 (10.5) 55.8 30.7 (5.3) 2.2 (3.7) 8.7 (1.1) 0.13 (−0.06, 0.33)
Göke et al46 104 858 57.6 (10.3) 51.8 31.4 (5.9) 5.5 (4.6) 7.7 (0.9)
−0.05 (−0.17, 0.06)
Matthews et al44 104 3118 57.5 (9.13) 53.5 31.8 (5.3) 5.7 (5.1) 7.3 (0.7) 0.00 (0.00, 0.1)
Seck et al42 104 1172 56.7 (9.6) 59.2 31.3 (5.1) 6.4 (5.8) 7.7 (0.9)
−0.03 (–)
Observational 
studies
Lee et al60 24 69 52.3 (12.8) 58.0 26.9 (3.9) 0.5 (0.5) 8.1 (0.8) 0.07 (−0.24, 0.37)
Gitt et al61 52 256 65.2 (11.1) 52.0 – 5.0 (4.2) 7.4 (0.7)
−0.10 (−0.24, 0.04)
Göke et al62 52 7410 62.6 (11.1) 54.0 30.8 (5.5) 5.8 (4.9) 7.7 (1.2)
−0.20 (−0.22, −0.09)
Morgan et al59 52 16,832 61.9 (11.4) 59.8 32.1 (5.5) 4.6 (3.8) 8.7 (1.4) 0.30 (–)
Notes: Data shown as mean (standard deviation) unless specified otherwise. Nauck et al41 and Seck et al;42 Göke et al45 and Göke et al;46 and Ferrannini et al43 and Matthews 
et al44 are based on the same RCTs, but with different follow-ups. aThe difference in change in HbA1c between treatment groups. – indicates data not reported.
Abbreviations: HbA1c, glycated hemoglobin; RCTs, randomized controlled trials.
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explain why the findings differ from those of the confound-
ing adjusted observational studies and the RCTs. It should 
be noted that Thayer et al28 did not aim for a comparison 
of effects across treatments. The RCT by Bergenstal et al18 
reported results outside the 95% CI of the other RCTs and 
must be seen as an outlier. Among studies comparing DPP-4i 
with sulfonylurea, the three observational studies reporting 
unadjusted effects59,61,62 show effect estimates of similar 
magnitude to the effect estimates in the confounding adjusted 
observational study60 and the RCTs.
The numbers from Tables 1 and 2 are presented graphi-
cally in Figures S1 and S2. More information on the RCTs 
and observational studies is found in Tables S1–S4.
Discussion
No clear differences in the available baseline characteristics 
of the study populations and in the effect estimates of the 
identified RCTs and observational studies were observed 
in this review. Hence, no efficacy–effectiveness gap was 
observed and no drivers of effectiveness were identified.
Despite examples where results from RCTs and obser-
vational studies seem not to agree,12–15 reviews that have 
systematically compared the results from RCTs and obser-
vational studies have found that effect sizes from RCTs 
and observational studies are often similar or do not differ 
systematically across a range of medical subjects63,64 and 
suggest that the theoretical efficacy–effectiveness gap may 
not be as widespread as often thought. This is in line with 
the findings in this review.
An efficacy–effectiveness gap with regard to DPP-4i 
(specifically vildagliptin) and sulfonylurea in relation to 
change in HbA1c has been investigated elsewhere;65 the 
effect of the individual drug, that is, change from baseline 
of the two drugs separately, was compared across five RCTs 
and the one observational study. Ahrén et al65 found that 
DPP-4i had a similar effect in the RCTs and the observa-
tional study, but that an efficacy–effectiveness gap may exist 
with regard to sulfonylurea because sulfonylurea proved 
more effective in RCTs than in the observational study. 
The study by Ahrén et al65 is based on other data than this 
Figure 2 Effect estimates of studies comparing glucagon-like peptide-1 with insulin.
Notes: Difference in mean change HbA1c ±95% confidence interval. The difference in change in HbA1c between treatment groups. Diamant et al25–27 are based on the same 
RCTs, but with different follow-ups. aTwo different cohorts analyzed and reported in the same publication. Red circle: RCTs. Blue filled square: observational studies with 
confounding adjustment. Blue open square: observational studies unadjusted for confounding.
Abbreviations: HbA1c, glycated hemoglobin; RCTs, randomized controlled trials.
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review because Ahrén et al65 included RCTs that compared 
DPP-4i with placebo (only using data on the active arm), 
and because the observational data were based on the full 
EDGE study,66 which was not included in this review because 
the EDGE study reported comparison of DPP-4i with other 
oral hypoglycemics and not specifically sulfonylurea. In 
this review article, the German part of the observational 
EDGE study62 was included. Also to be mentioned, it is 
unclear how Ahrén et al65 identified the included studies, as 
it was not based on a systematic literature search as in this 
review. This review used the comparison of two drugs as 
outcome (change with DPP-4i subtracted from change with 
sulfonylurea) and did not assess the effect of the individual 
drugs (change for DPP-4i and sulfonylurea, respectively) 
as done by Ahrén et al.65
Possible biases in this review could work in opposite 
directions, and thus hide an actual efficacy–effectiveness gap. 
No identification of an efficacy–effectiveness gap could be 
a net result of such biases. Possible biases in this review are 
described in the following points:
1) Unmeasured confounding is always a potential problem 
in observational studies, and several of the observational 
studies reported effects not adjusted for potential confound-
ers. Selection bias may also have been a problem in the 
observational studies because inclusion criteria were only 
partly clear in the observational studies, and all observational 
studies either excluded participants with missing information 
or did not report how missing data were handled. From this 
it is clear that future observational studies in the investigated 
area of this review can be designed to a higher degree to avoid 
biases and include confounding adjustment in the analyses. 
A descriptive approach to identify key drivers of bias was 
used to assess the observational studies. As stated, the aim 
of this review was not to assess the quality of the studies in 
detail with a more comprehensive and validated tool. Rather, 
the descriptive approach was found sufficient to identify 
Figure 3 Effect estimates of studies comparing dipeptidyl peptidase-4 inhibitors with sulfonylurea.
Notes: Difference in mean change HbA1c ±95% confidence interval. The difference in change in HbA1c between treatment groups. Nauck et al41 and Seck et al;42 Göke et 
al45 and Göke et al;46 and Ferrannini et al43 and Matthews et al44 are based on the same RCTs, but with different follow-ups, Red circle: RCTs. Blue filled square: observational 
studies with confounding adjustment. Blue open square: observational studies unadjusted for confounding.
Abbreviations: HbA1c, glycated hemoglobin; RCTs, randomized controlled trials.
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potential flaws in the observational studies. 2) The limited 
number of studies in this review may also have affected the 
findings. Especially, the number of observational studies 
was lower than the RCTs. One could speculate whether the 
use of a hard end point (e.g., death) would have led to a 
higher number of available observational studies. However, 
it would probably limit the amount of available RCTs. As to 
the number of available studies, publication bias may also 
have affected our results. Probably, publication bias will be 
most pronounced among observational studies. However, 
the effect estimates of the observational studies look fairly 
symmetric, when looking at Figures 2 and 3, which suggest 
no publication bias. However, a specific study on this topic is 
needed to draw final conclusions. It is important to note that 
effect estimates from the same RCTs at different follow-up 
time points are listed in Tables 1 and 2. However, as there 
was no overall effect estimated, we did not double count these 
studies in any pooled analysis. In the descriptive comparison 
of effect estimates, we wanted to make it complete, and, 
therefore, all effect estimates were listed. 3) Characteristics 
of the study populations and other features of the studies 
may differ in ways not quantified in the data extraction. The 
assessed characteristics were restricted to the information 
that was available in both the RCTs and the observational 
studies. The observational studies often included more 
information on patient characteristics than the RCTs, for 
example, distribution of comorbidities and comedication of 
the study population. Delivery of care and adherence to the 
treatments is an area where RCTs and observational stud-
ies may differ with a possible impact on treatment effect 
as, for example, seen in osteoporosis treatment.67 However, 
such information was not available and, therefore, cannot 
be compared across study designs. Future studies based on 
patient-level data rather than systematic reviews may be 
better suited to investigate the potential drivers of effective-
ness not observed in this review, for example comorbidity, 
comedication, delivery of care, and adherence to treatment. 
Studies on patient-level data are also useful to investigate 
effect modification of, for example, drug and patient char-
acteristics, which will give insights in possible drivers of 
effectiveness. 4) It is possible that the observational studies 
were designed to be comparable with the RCTs with regard 
to, for example, the study population. If so, this would result 
in no efficacy–effectiveness gap because of differences in the 
study populations when compared in this review. However, 
this was neither explicitly stated in any of the observational 
studies nor could it be deduced from the listed inclusion 
criteria. 5) If the studies have had similar subgroup analyses 
across RCTs and observational studies, this could be used 
to investigate the potential efficacy–effectiveness gap even 
further. However, few subgroup analyses were conducted in 
the included studies, and not in a way that we could compare 
across study designs. 6) The results of this review should be 
interpreted in the light of GLP-1 and DPP-4i being analyzed 
on drug class level. It would require many more studies to 
do subgroup analyses on the individual drugs, and not all 
observational studies give information on drug names and 
doses. Tables S1–S4 hold the available information on drug 
names and doses investigated in the included studies.
In this review, HbA1c was used as outcome measure 
because it is the common effect measure of glucose-lowering 
drugs. It is important to note that this review did not aim to do 
a full evaluation of the included glucose-lowering drugs. Such 
evaluation should involve more parameters than solely change 
in HbA1c, for example cardiovascular events, hypoglycemic 
events, and weight change. We used this outcome measure as 
an example to study a potential efficacy–effectiveness gap. 
As described in the Methods section, pooled analyses were 
not the aim of this review. For pooled analyses to make sense, 
this would require more homogeneous studies, for example 
with regard to the duration of study, and it is likely that very 
few studies would be included in such analyses. Instead, the 
present review gives an insight into the published studies in 
this area, and with the inclusion of heterogenetic studies, for 
example with varying study duration, possible explanation 
of an efficacy–effectiveness gap was investigated.
To conclude, no efficacy–effectiveness gap between RCTs 
and observational studies comparing GLP-1 with insulin or 
DPP-4i with sulfonylurea was observed. However, the limited 
number of studies and potential problems with confounding 
adjustment, selection- and information bias in the observa-
tional studies, may have hidden a true efficacy-effectiveness 
gap. Hence, the existence of an efficacy-effectiveness gap 
cannot be fully excluded. No potential drivers of effectiveness 
were identified among age, sex, BMI, time since diagnosis 
of type 2 diabetes mellitus, baseline HbA1c, publication 
year, duration of study, and number of patients in the study. 
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